Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma
Anticancer Research · 2024
DOI: 10.21873/anticanres.17366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Sonexai Kidoikhammouan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand. Hauptthemen laut MEDLINE: Gemcitabine, Cholangiocarcinoma, Deoxycytidine, Drug Resistance, Neoplasm.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand.
- Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
- Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
- Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
- Division of Health and Applied Science, Faculty of Sciences, Prince of Songkla University, Hat Yai, Thailand.
- Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; wunchana@kku.ac.th.
Zitieren
APA
Kidoikhammouan, S., Lert-Itthiporn, W., Deenonpoe, R., Saengboonmee, C., Obchoei, S., Wongkham, S., & Seubwai, W. (2024). Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17366
Vancouver
Kidoikhammouan S, Lert-Itthiporn W, Deenonpoe R, Saengboonmee C, Obchoei S, Wongkham S, et al. Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma. Anticancer Research. 2024. doi:10.21873/anticanres.17366
BibTeX
@article{Kidoikhammouan2024,
author = {Kidoikhammouan, Sonexai and Lert-Itthiporn, Worachart and Deenonpoe, Raksawan and Saengboonmee, Charupong and Obchoei, Sumalee and Wongkham, Sopit and Seubwai, Wunchana},
title = {Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17366}
}
EUVIMED